Improving the Outcome of Bad-Acting Hormone Receptor–Positive Breast Cancer

Mené sur 325 patientes atteintes d'un cancer du sein HR+ HER2- avec mutation au niveau du gène PIK3CA et de stade avancé ou métastatique (durées médianes de suivi : 21,3 et 21,5 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'inavolisib (un inhibiteur de PI3KCA) à un traitement combinant palbociclib et fulvestrant

Résumé en anglais

The treatment approach for patients with estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer has changed dramatically over the past 20 years. In the past, the usual approach involved administering the available single agents (tamoxifen, aromatase inhibitors, and fulvestrant) sequentially until endocrine sensitivity was exhausted and then pivoting to chemotherapy. Although a variety of mechanisms of resistance to endocrine therapy were identified during preclinical work, clinical options to exploit these findings were largely lacking until recently. Drug development began to focus on signaling pathways and somatic mutations that transform endocrine-sensitive breast cancer into a drug-resistant phenotype (...)